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Hemoglobin E (HbE) is caused by a G→A mutation at codon 26 of the β-globin gene, which substitutes Glu→Lys. This mutation gives rise to
functional but unstable hemoglobin and activates a cryptic splice site causing mild anemia. HbE reaches a carrier frequency of 60–80% in some
Southeast Asian populations. HbE causes serious disease when co-inherited with a β-thalassemia mutation. In this study, we report the creation
and evaluation of humanized transgenic mice containing the βE mutation in the context of the human β-globin locus. Developmental expression of
the human βE locus transgene partially complements the hematological abnormalities in heterozygous knockout mice (muβth-3/+) and rescues the
embryonic lethality of homozygous knockout mice (muβth-3/th-3). The phenotype of rescued mice was dependent on the transgene copy number.
This mouse model displays hematological abnormalities similar to HbE/β-thalassemia patients and represent an ideal in vivo model system for
pathophysiological studies and evaluation of novel therapies.
© 2006 Elsevier Inc. All rights reserved.Keywords: Hemoglobin E; BAC transgenic mice; β-Thalassemia; HbF inductionHemoglobin E (HbE) is the common hemoglobin variant,
most prevalent in the rapidly expanding populations of
Southeast Asia, but it is also encountered with increasing
frequency in Europe, North America, and Australia due to
increasing immigration from Southeast Asia [1]. Although HbE
was first identified in 1954 [2] there are still uncertainties about
aspects of the pathophysiology of the associated hemoglobin-
opathy. Both heterozygotes and homozygotes aremildly anemic,
with microcytic and hypochromic erythrocytes. This is consis-
tent with the thalassemic nature of the βE mutation, in which a
cryptic donor splice site is activated by the G→A mutation in
exon 1 of the β-globin gene [3]. However, when the βE allele
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doi:10.1016/j.ygeno.2006.03.009heterozygous state, an often severe but variable anemia is
produced, with hemoglobin levels from 3 to 11 g/dl [4].
Five β-thalassemia mouse models have been described.
These models comprise a naturally occurring deletion (Hbbth-1)
[5], an insertional disruption (Hbbth-2) [6], or a complete
deletion of the mouse β-globin genes (Hbb0 and Hbbth-3) [7,8].
A range of disease severity including mild anemia, thalassemia
intermedia, or embryonic lethality was observed in these
models. These mice mimic the β-thalassemia phenotype seen
in humans and can be used to study approaches to gene therapy
based on gene supplementation [9,10]. However, none of these
models reproduces β-thalassemia as seen in humans at the
genotypic level, thus limiting the development of therapeutic
strategies that are not based on gene supplementation. An
additional knock-in model carrying a single copy of the human
β-globin gene with the IVSII-654 C→T splicing mutation in
place of the mouse β-globin genes (Hbbth-4) was developed
[11]. This model is valuable for the in vivo development of
antisense oligonucleotides therapy to restore splicing specificity.
Fig. 1. Characterization of the βE transgene in transgenic mice. (A) FISH
analysis of biotin-labeled probe from pEBAC/148β onto chromosomes obtained
from fibroblast cells cultured from transgenic founder mouse line 1. (B)
Southern blot analysis of EcoRI- and HpaI-digested genomic DNA from F1
transgenic mice. Lanes H1 and H2, 5 and 10 μg of human genomic DNA,
respectively; lanes L1–L3, 10 μg of genomic DNA from transgenic lines 1, 2,
and 3, respectively. The bands corresponding to hybridization with the human
β-globin (2.2 kb) and human δ-globin (2.0 kb) genes are shown.
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erated using a 12-kb DNA fragment containing human βE- and
human α-globin genes linked to the human β-globin locus
control region [12]. Mice expressing the human βE gene on a
full mouse α-globin knockout and a partial mouse β-globin
knockout background have red cell abnormalities similar to
those of HbE and HbE/β0-thalassemia patients. However, the
lack of the γ-globin genes and the absence of other cis-acting
regulatory elements that control the expression of the β-globin
locus in the transgene fragment used to generate this model have
limited its use for pharmacological up-regulation of γ-globin
gene expression, a potential therapy for HbE/β-thalassemia
[13,14].
We have used a 183-kb genomic fragment containing the
human β-globin locus to generate transgenic mice [15].
Developmentally appropriate expression of the globin genes
from the human β-globin locus transgene was able to rescue
the embryonic lethal homozygous β-globin knockout embryos
(muβth-3/th-3) [15]. Using the GET Recombination system [16],
we introduced several common β-thalassemia mutations [17–
19], including βE and a deletion of codons 41–42 (–TTCT)
in the β-globin gene [20], within the human β-globin locus
contained in a 183-kb genomic fragment. We have recently
reported the first humanized mouse model for the deletion of
codons 41–42 [21]. Unlike the situation with the normal
human β-globin locus [15], these mutant mice fail to show
any phenotypic complementation in heterozygous or homo-
zygous knockout mice. This is a valuable model for gene
correction in hemopoietic stem cells and for studying the
effects of HbF inducers in vivo in a humanized thalassemic
environment.
In this study, we report the creation and evaluation of
humanized transgenic mice containing the βE mutation in the
context of the human β-globin locus. We show that these mouse
models display hematological abnormalities at phenotypic and
genotypic levels similar to HbE homozygotes and HbE/β-
thalassemia patients. These mice represent an ideal in vivo
model system for pathophysiological studies and evaluation of
novel therapies.
Results
Transgenic founder mice contain a single transgene
integration site and two to four copies of the human βE transgene
We generated five transgenic founder mice, of which three
transmitted the transgene to progeny. Using fluorescence in situ
hybridization (FISH) analysis, we showed that transgenic line 1
(Fig. 1A) and the other two transmitting lines contained a single
integration site of the transgene (data not shown). Transgenic
line 1 contained four copies of the transgene, and lines 2 and 3
contained two copies, as determined by Southern blot
hybridization (Fig. 1B). The overall integrity of the transgene
fragment evaluated by multiplex PCR using primer pairs for 5′
HS-5, 5′HS-2, human ϵ-globin, human γ-globin, and human δ-
globin genes as previously described [21] showed that all
founders produced all the expected fragments (data not shown).The overall functionality of the human βE-globin locus
transgene in these mice was evaluated by complementation of
the embryonic lethality of homozygous knockout muβth-3/th-3
embryos. We bred all transmitting lines with the heterozygous
β-globin knockout mice (muβth-3/+) [8] to produce mice
hemizygous for the transgene on a heterozygous knockout
background (huβE/0, muβth-3/+), referred to as “double hetero-
zygous” (DH). DH mice were then bred together to generate
mice hemizygous (huβE/0, muβth-3/th-3) or homozygous for the
transgene (huβE/E, muβth-3/th-3) on a homozygous knockout
background, referred to as “rescued mice”.
Human βE transgene expression in adult transgenic mice is
copy number dependent
To determine the relative expression of the human βE-
globin and the endogenous mouse β-globin genes (βmaj and
βmin), we performed a semiquantitative RT-PCR analysis
using primers flanking exons 1 and 2 of the β-globin gene.
These primers amplify equally well on the mouse and human
β-globin mRNAs and produce a 252-bp product from both
mouse and human β-globin. The human β-globin cDNA
could be distinguished from the mouse β-globin cDNA by
digestion with NcoI, which cuts only the mouse β-globin
cDNA PCR product into two 126-bp fragments (Fig. 2A). We
demonstrated that the human βE-globin mRNA was detected
in the peripheral blood of mice carrying the hemizygous
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(Fig. 2B). An increase in the expression of the human βE-
globin relative to the mouse β-globin was observed in DHmice
for all three lines (Fig. 2B). The finding that line 1, containing
four copies of the transgene, has a higher level of human β-
globin mRNA than the other two lines (two copies of the
transgene) indicates that transgene expression increases with an
increase in transgene copy number. We obtained similar results
with transgenic mice carrying the normal human β-globin locus
[15].
Aberrant splicing of the βE-globin pre-mRNA in the βE
transgenic mice
To determine whether the βE-globin pre-mRNA in trans-
genic mice is aberrantly spliced as it is in humans, we
performed RT-PCR analysis on RNA derived from bone
marrow. Aberrant splicing of the βE-globin pre-mRNA should
result in a PCR product that is truncated by deletion of 16Fig. 2. Expression of the human βE-globin at mRNA level. (A) Schematic
diagram for the relative quantitation of the mouse and human βE-globin mRNA
in total RNA from peripheral blood. (B) RT-PCR analysis as in panel A. M1,
molecular weight marker IX (Roche); WT, wild-type C57BL/6 mouse; T1–T3,
βE transgenic mice on a wild-type mouse background; DH1–DH3, βE
transgenic mice on a muβth-3/+ background, lines 1–3, respectively. (C) Sche-
matic diagram for the detection of aberrant splicing due to the βE mutation from
bone marrow total RNA by RT-PCR. (D) RT-PCR analysis as in panel C. M1,
molecular weight marker IX (Roche); M2, molecular weight marker X (Roche);
H, normal human blood; T, bone marrow from transgenic mouse carrying the
normal human β-globin locus on a wild-type background; DH1–DH3, bone
marrow from βE transgenic mice on a muβth-3/+ background, lines 1–3,
respectively.nucleotides from the 3′ end of exon 1 (Fig. 2C). All three DH
mouse lines showed the presence of a 303-bp product of
correctly spliced βE-globin mRNA and a 287-bp product
(deletion of 16 bp) of aberrantly spliced βE-globin mRNA (Fig.
2D). This result confirmed that the βE G→A mutation from the
transgene locus in transgenic mice produces the same aberrant
spliced product found in patients carrying the βE mutation.
Thus this model is valuable for the in vivo development of
antisense oligonucleotides to restore splicing specificity, a
potential therapeutic approach to splicing defects in HbE/β-
thalassemia patients [22,23].
Human βE transgene expression complements hematological
abnormalities in the mu βth-3/+ mice
The hematologic indices of the βE, muβth-3/+, and wild-type
mice at 6–8 weeks of age are summarized in Table 1. The
muβth-3/+ mice are more anemic compared to human β-
thalassemia heterozygotes (β-thalassemia traits), as is reflected
in the markedly decreased hemoglobin concentration, hemat-
ocrit and red blood cell (RBC) count, as well as by the increased
red cell distribution width (RDW) and reticulocyte count. The
red cells from such mice also show marked hypochromia,
anisocytosis, poikilocytosis, and target cells in comparison to
normal mouse red cells (Table 1, Figs. 3A and 3B). However,
the reduction in mean cell volume and mean cell hemoglobin is
less than in human β-thalassemia heterozygotes. Furthermore,
there is no indication of any compensatory erythropoiesis in the
muβth-3/+ mice as reflected by a dramatic reduction in red cell
counts, unlike in human β-thalassemia heterozygotes, in which
there is a compensatory erythropoiesis resulting in an elevated
RBC count [24]. This appears to be due to the highly efficient
removal of immature red cell precursors expressing an excess of
α-globin chains [25]. The presence of the human βE-globin
locus transgene on a wild-type mouse background did not have
any noticeable effect on mouse hematology (data not shown).
However, the presence of the human βE-globin locus transgene
on a heterozygous knockout background (huβE/0, muβth-3/+)
partially complemented the hematological abnormalities that
are found in the muβth-3/+ mice (Table 1, Fig. 3C), although
there was some variability in the degree of complementation
among the three human βE mouse lines (Table 1).
Spleen and liver weights of the βE, muβth-3/+, and wild-
type mice were determined. The muβth-3/+ mice showed a
highly significant increase in spleen weight compared to wild-
type mice (Table 1). In all three βE DH mouse lines,
expression from the human βE locus allowed complementa-
tion of the spleen pathology (Table 1). The degree of com-
plementation in spleen pathology correlated well with the
normalization of hematologic values, with the βE mouse line
3 showing the lowest hemoglobin level and having the largest
spleen (Table 1). There was no difference in the ratio for liver
between wild-type, muβth-3/+, and all βE DH mouse lines
(data not shown). The elevated serum bilirubin concentration
in muβth-3/+ indicates increased red cell turn over and
hemolysis. The high reticulocyte counts and low red blood
cell counts indicated that both production and destruction of
Table 1
Full blood examination of the βE mice compared to wild-type and muβth-3/+ mice
Genotype Hb
(g/dl)
HCT (%) RBC
(109/ml)
MCV (fl) MCH (pg) RDW (%) Retic. (%) Spleen
(mg)
Bilirubin
(mg/dl)
Wild-type C57BL/6 muβ+/+
(n = 15)
16.3 ± 1.1 49.4 ± 3.0 10.9 ± 0.7 51.7 ± 1.2 15.2 ± 1.2 13.6 ± 1.3 5.5 ± 3.3 77 ± 16 0.13 ± 0.04
Heterozygous KO muβth-3/+
(n = 12)
8.4 ± 0.5
P = 0.001
28.5 ± 1.1
P = 0.001
5.1 ± 0.5
P = 0.0003
45.8 ± 2.7
P = 0.04
13.8 ± 0.6
P = 0.04
36.6 ± 1.3
P = 0.0002
37.4 ± 6.3
P = 0.004
556 ± 52
P = 0.004
0.41 ± 0.17
P = 0.04
Double-heterozygous mice:
huβE/0, muβth-3/+
Line 1 (n = 12) 15.3 ± 1.0
P > 0.05
50.2 ± 0.7
P > 0.05
10.0 ± 0.3
P > 0.05
50.3 ± 1.1
P > 0.05
14.3 ± 0.7
P > 0.05
17.1 ± 1.5
P > 0.05
5.1 ± 2.1
P > 0.05
79 ± 14
P > 0.05
0.10 ± 0.02
P > 0.05
Line 2 (n = 12) 14.7 ± 0.7
P > 0.05
51.4 ± 2.2
P > 0.05
10.1 ± 0.4
P > 0.05
50.8 ± 0.6
P > 0.05
14.8 ± 0.3
P > 0.05
16.0 ± 2.7
P > 0.05
5.5 ± 0.8
P > 0.05
95 ± 10
P > 0.05
0.12 ± 0.02
P > 0.05
Line 3 (n = 10) 13.3 ± 0.1
P = 0.04
47.9 ± 1.1
P > 0.05
9.9 ± 0.4
P > 0.05
49.5 ± 1.4
P > 0.05
14.9 ± 0.2
P > 0.05
20.9 ± 1.4
P = 0.002
6.3 ± 1.2
P > 0.05
130 ± 16
P = 0.01
0.15 ± 0.04
P > 0.05
Rescued mice:
huβE/0, muβth-3/th-3 or
huβE/E, muβth-3/th-3
huβE, 8 copies (n = 3),
line 1 × line 1
17.7 ± 1.4
P > 0.05
51.8 ± 2.1
P > 0.05
12.4 ± 2.0
P > 0.05
45.6 ± 3.2
P > 0.05
14.4 ± 1.2
P > 0.05
21.0 ± 2.3
P = 0.01
7.3 ± 0.9
P > 0.05
NA NA
huβE, 6 copies (n = 3),
line 1 × line 2
11.2 ± 0.5
P = 0.005
30.8 ± 0.8
P = 0.009
5.6 ± 0.4
P = 0.001
47.1 ± 5.0
P > 0.05
27.0 ± 1.9
P = 0.002
30.4 ± 3.5
P = 0.004
15.3 ± 0.8
P = 0.03
NA NA
huβE, 4 copies (n = 3),
line 2 × line 2
7.4 ± 0.4
P = 0.001
11.0 ± 0.7
P = 0.002
2.9 ± 2.4
P = 0.004
40.4 ± 3.0
P = 0.009
34.0 ± 2.0
P = 0.0008
37.9 ± 2.6
P = 0.0007
40.2 ± 5.1
P = 0.002
NA NA
The hematological values are expressed as means ± SD. Hb, hemoglobin concentration; HCT, hematocrit; RBC, red blood cells; MCV, mean corpuscular volume;
MCH, mean corpuscular hemoglobin; RDW, red cell distribution width, Retic., reticulocytes. The p value of Student t tests comparing each group of the HbEmice with
wild-type mice controls are shown. NA, not analyzed.
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type mice (Table 1). These hematological abnormalities were
partially complemented by the human βE locus transgene in
DH mice.
Developmental expression of the huβE transgene locus rescues
embryonic lethal muβth-3/th-3 mice
To ascertain if the human βE locus transgene in mice is able
to rescue the lethality of the muβth-3/th-3 embryos, we further
intercrossed the DH mice. Genotyping was performed by
multiplex PCR using primers specific for the human β-globin
gene, mouse β-globin gene, and HPRT cassette in the knockout
mice as previously described [15]. With this breeding strategy,
1 in 16 pups are expected to be homozygous for the HbE locus
transgene on a homozygous β-globin knockout background
(homozygous rescued mice) and 2 in 16 pups are expected to be
hemizygous for the transgene on a homozygous β-globin
knockout background (hemizygous rescued mice). We screened
162, 81, 115, and 82 mice from breeding of line 1 × line 1, line
2 × line 2, line 3 × line 3, and line 1 × line 2, respectively, and
obtained 26, 14, 19, and 17 rescued mice, respectively. The
rescued progeny were obtained from all three mouse lines with
the expected ratio; however, 65% of rescued progeny died
within the first day after birth. Only some of the progeny (35%)
survived to adulthood. Since the viability of the rescued pups
after birth could depend on the level of the human βE
expression, transgene copy number was determined by FISH.
All of the adult rescued mice from line 1 × line 1 (Fig. 4A), line
1 × line 2, and line 2 × line 2 (data not shown) were
homozygous for the transgene (i.e., eight, six, and four copies,respectively). The finding that no adult rescued mice hemizy-
gous for the transgene were obtained indicates that the dosage
of the βE transgene on the homozygous knockout background
has a direct effect on the severity of the rescued mice. These
findings confirm our studies with the normal human β-globin
locus, of which at least four copies are necessary to rescue the
embryonic lethal muβth-3/th-3 embryos [15].
Red blood cell abnormalities were also restored by the βE
transgene in rescued mice from breeding of line 1 × line 1
(eight copies of transgene), although the RDW remained
somewhat elevated (Table 1), with some target cells and
hypochromia still detectable (Fig. 3D). Interestingly, cross-
breeding of mice from line 1 × line 2 resulted in adult rescued
mice with an intermediate hematological picture indicating
incomplete complementation in mice with an intermediate
transgene copy number (six copies of the transgene) (Fig. 3E).
A more severe phenotype was observed in rescued mice
containing the lowest transgene copy number (four copies of
the transgene from line 2 × line 2) (Fig. 3F).
The presence of the heterotetramer hemoglobin (muα2/
huβE2)
and individual globin chain in the βE mice was demonstrated
using cellulose acetate and Triton X acid urea gel electropho-
resis (Figs. 4B and 4C). The βE DH mouse contained a slower
migrating hemoglobin heterotetramer comprising mouse α-
globin and human βE-globin chains (muα2/
huβE2) (Fig. 4B).
Analysis of adult rescued mouse blood samples showed the
presence of only the muα2/
huβE2 hemoglobin (Fig. 4B). The
heterotetrameric hemoglobin was also analyzed by HPLC.
Although the human βE-globin chain was found to elute at
the same position as the mouse β-globin chain, analysis of the
β-globin fraction by tandem mass spectroscopy yielded a mass
Fig. 3. Red blood cell morphology of βE transgenic mice compared with wild-type and muβth-3/+ mice. (A) Wild-type mouse; (B) muβth-3/+ mouse; (C) βE DH mouse
with four copies of the transgene; (D) βE rescued mouse with eight copies of the transgene; (E) βE rescued mouse with six copies of the transgene; (F) βE rescued
mouse with four copies of the transgene. Target cells and hypochromic cells are denoted by red and black arrows, respectively.
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mass ratio of the human βE-globin chain. Last, Triton X acid
urea gel of a blood sample from an adult βE rescued mouse
showed the presence of only the human βE-globin chain and the
total absence of mouse β-globin chains (Fig. 4C).
Discussion
A large number of mutations have been described in the
human β-globin locus causing thalassemia or various hemo-
globinopathies [26]. However, only the HbS variant has been
modeled up to now in the context of the intact human β-globin
locus in transgenic mice [27]. The βE mutation results in both a
variant hemoglobin and a splicing defect, since the mutation is
present in an exon and also activates a cryptic splice site. The
normal splicing of the mutant gene results in a variant β-globin
chain, while aberrant splicing deletes 16 bp of exon 1 from the
mature mRNA. Restoration of correct splicing of βE mRNA by
antisense oligonucleotides [22,23] may thus be a possible way
to ameliorate the severity of HbE/β-thalassemia patients.Alternatively, targeted up-regulation of the γ-globin genes
expression may be beneficial for βE as well as other types of
β-globin mutations [13,14].
Large genomic inserts in BACs are more likely to contain the
whole set of regulatory elements required for tissue-specific and
position-independent transgene expression [28]. The develop-
ment of methods for engineering BACs and the use of BACs in
transgenesis have allowed the discovery of new genes by
complementation of mutations, the identification of key
regulatory sequences within genomic loci that are crucial for
the proper expression of genes, and the design of improved
animal models of human genetic diseases [29]. To produce a
mouse model of HbE/β-thalassemia that recapitulates not only
the phenotypic symptoms but also the correct underlying
molecular defects as found in patients, we generated a
transgenic/knockout mouse model for the βE mutation in the
context of the intact genomic human β-globin locus from a 205-
kb β-globin BAC clone. These mice exhibit hematological and
pathophysiological symptoms mirroring those of human HbE
and HbE/β-thalassemia diseases. A low dosage of the human
Fig. 4. Characterization of βE rescued mice. (A) FISH analysis of an adult
rescued mouse (line 1 × line 1). Hybridization of the probe can be clearly seen on
two homologous chromosomes (inset). (B) Cellulose acetate electrophoresis of
hemoglobin tetramers in whole mouse blood. (C) Globin chain separation in
whole mouse blood by Triton X acid urea gel. WT, wild-type; KO, heterozygous
knockout; T, βE transgenic on a normal mouse background; DH, βE transgenic
on a heterozygous knockout background; R, βE transgenic on a homozygous
knockout back ground (rescued).
314 D. Jamsai et al. / Genomics 88 (2006) 309–315βE locus transgene on a muβth-3/th-3 background is associated
with severe anemia and neonatal death, while an increased
dosage of the human βE transgene allows some mice to develop
to adulthood with hematological abnormalities similar to those
of HbE/β-thalassemia patients.
In conclusion, the βE mouse model generated in this study
complements existing models that allow preclinical testing of
gene therapy approaches. They will be of particular value in
allowing evaluation of therapeutic approaches that depend on
the pharmacological reversal of the splicing defect in the
mRNA coding for βE-globin, or the reactivation of fetal
globin gene expression, as well as pathophysiological studies
of iron overload, oxidative stress, and red cell membrane
abnormalities.
Materials and methods
Insertion of the βE mutation into a human β-globin BAC clone
Two-step GET Recombination in combination with the EcoRI/KanR
counterselection cassette was used to introduce the βE mutation into
pEBAC148/β, a 205-kb BAC carrying the entire human β-globin locus. In
the first stage of GET Recombination, the EcoRI/KanR cassette was inserted into
intron 1 of the human β-globin gene. This was subsequently knocked out in a
second round of GET Recombination by a PCR fragment from genomic DNA of
a homozygous βE subject [20].Preparation of a 183-kb βE-globin locus for microinjection
BACDNAwas purified by cesium chloride gradient ultracentrifugation. The
183-kb genomic insert containing the human βE-globin locus was released from
the vector backbone by digestion of 50 μg of purified BAC DNAwith NotI and
separated by pulsed-field gel electrophoresis as previously described [15,21].
The DNA fragment was microinjected into C57BL/6 fertilized oocytes to
generate transgenic mice.
Transgene analysis
FISH analysis using the pEBAC148/β probe on fibroblasts grown from
mouse tail samples was used to determine the number of integration sites as
previously described [15,21]. The transgene copy number was determined by
Southern blot analysis using the human β-globin probe amplified by the
LUG1A/LUG2A primers [15,21]. Genomic DNA from transgenic mice was
extracted from tail biopsies, and control human genomic DNA was extracted
from peripheral blood by phenol/chloroform extraction. The DNA concentration
was measured by spectrophotometry. A total of 10 μg of genomic DNA of each
sample was digested with EcoRI and HpaI overnight. The high degree of
homology exhibited by all the members of the human β-globin gene family with
respect to the region amplified by the LUG1A/LUG2A primers allows
simultaneous detection of 2.2-kb human β-globin and 2.0-kb human δ-globin
fragments. The transgene copy number was estimated by comparing the relative
intensity of the human β-globin fragment from human genomic DNA (two
copies/cell) to the intensity of the human β-globin fragment present in
transgenic mice using Gene tools (Syngene, UK).
Quantitation of human and mouse β-globin mRNA
Isolation of total RNA from peripheral blood and bone marrow samples
was performed using the TRI-BD reagent (Molecular Research Center, Inc.).
RNA was converted into cDNA using SuperScript II reverse transcriptase
(Gibco BRL). cDNA template was used as template for PCR using primers
Exon1-F (5′-GATGAAGTTGGTGGTGAGGCCCT-3′) and Exon2-R (5′-
CCTGAAGTTCTCAGGATCCAC-3′). These primers anneal to identical
sequences on the mouse and human β-globin cDNAs to yield a 252-bp
product. The human β-globin mRNA product could be distinguished from the
mouse β-globin mRNA product by digestion with NcoI, which cuts the mouse
β-globin PCR product (but not the human β-globin PCR product) into two
126-bp fragments.
Determination of aberrant splicing induced by the βE mutation
The primers used to determine aberrant splicing of the human β-globin pre-
mRNA were Exon1 βE-F (5′-AGGTGAACGTGGATGAAGTTG-3′) and
Exon3-R (5′-AGTGATGGGCCAGCACACAG-3′). These primers amplify a
303-bp product from correctly spliced βE mRNA and a 287-bp product (deletion
of 16 bp) from aberrantly spliced βE mRNA.
Hematologic analysis
EDTA blood was used for hematological analysis. Blood smears were
stained with Wright's stain (Sigma). Hematologic profiles were obtained with an
automatic blood counter (Roche Cobas Helios hematology analyzer).
Hemoglobin analysis was performed as previously described [30]. Samples
containing approximately equal amounts of hemoglobin were run on cellulose
acetate membranes (Helena Laboratories). Hemoglobin bands were visualized
by Ponceau S staining. Globin chain separation was performed by Triton X acid
urea gel electrophoresis as previously described [31].Acknowledgments
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